Luca Richeldi

Q: What Schools Are Affiliated With Luca Richeldi

Luca Richeldi is affiliated with the following schools: University of Oxford, University of Michigan, University of Modena and Reggio Emilia, Università Cattolica del Sacro Cuore, University of Southampton

Luca Richeldi's AcademicInfluence.com Rankings

Luca Richeldi

Philosophy

#6347

World Rank

#9372

Historical Rank

Logic

#3523

World Rank

#4701

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Luca Richeldi's Degrees

Doctorate Medicine University of Modena and Reggio Emilia
PhD Respiratory Medicine University of Modena and Reggio Emilia

Why Is Luca Richeldi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luca Richeldi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. (2011) (5108)
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. (2013) (2746)
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline (2018) (2039)
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. (2014) (1576)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. (2015) (1317)
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society (2020) (1243)
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. (2011) (922)
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. (2019) (875)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. (2016) (849)
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features (2015) (704)
Idiopathic pulmonary fibrosis (2012) (635)
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. (2017) (629)
Idiopathic pulmonary fibrosis (2017) (565)
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study (2006) (540)
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017) (457)
HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. (1993) (448)
The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic (2020) (343)
An update on the diagnosis of tuberculosis infection. (2006) (341)
Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017) (336)
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. (2016) (332)
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. (2005) (282)
Idiopathic pulmonary fibrosis: pathogenesis and management (2018) (267)
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan (2013) (263)
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. (2020) (241)
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline (2022) (215)
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. (2016) (208)
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume (2016) (184)
Performance of tests for latent tuberculosis in different groups of immunocompromised patients. (2009) (171)
Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial (2018) (169)
Nintedanib with Add‐on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial (2017) (166)
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials (2013) (163)
Macrolides for chronic asthma. (2005) (161)
Use of a T-cell interferon-γ release assay for the diagnosis of tuberculous pleurisy (2007) (157)
Non-steroid agents for idiopathic pulmonary fibrosis. (2010) (155)
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis (2012) (155)
Prevalence and prognosis of unclassifiable interstitial lung disease (2012) (155)
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria (2017) (153)
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. (2020) (150)
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. (2004) (149)
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease (2017) (144)
Performance of Commercial Blood Tests for the Diagnosis of Latent Tuberculosis Infection in Children and Adolescents (2009) (139)
Interaction of genetic and exposure factors in the prevalence of berylliosis. (1997) (136)
Post-COVID-19 global health strategies: the need for an interdisciplinary approach (2020) (136)
Combination therapy: the future of management for idiopathic pulmonary fibrosis? (2014) (134)
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. (2009) (128)
A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective (2017) (128)
CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. (2015) (127)
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial (2018) (126)
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. (2020) (121)
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. (2011) (119)
Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history (2016) (118)
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. (2019) (117)
Corticosteroids for idiopathic pulmonary fibrosis. (2003) (111)
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis (2015) (109)
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? (2018) (109)
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials (2019) (107)
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (2013) (104)
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis (2017) (96)
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients (2003) (96)
Immunomodulatory agents for idiopathic pulmonary fibrosis. (2003) (95)
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections (2004) (95)
Major histocompatibility locus genetic markers of beryllium sensitization and disease. (2001) (93)
Non-steroid agents for idiopathic pulmonary fibrosis (Intervention Review) (2010) (93)
Idiopathic pulmonary fibrosis: CT and risk of death. (2014) (88)
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis (2016) (88)
Rifabutin for treating pulmonary tuberculosis. (2007) (87)
Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis (2019) (84)
Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. (2012) (84)
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. (2013) (83)
Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis (2018) (82)
Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. (2014) (81)
Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good (2012) (77)
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. (2015) (75)
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis (2019) (73)
Early Diagnosis of Subclinical Multidrug-Resistant Tuberculosis (2004) (72)
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study (2017) (71)
Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis (2016) (71)
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis (2018) (71)
Inactivation of polymerase inhibitors for Mycobacterium tuberculosis DNA amplification in sputum by using capture resin (1995) (70)
Nintedanib for the treatment of idiopathic pulmonary fibrosis (2018) (70)
Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment (2014) (69)
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. (1998) (69)
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. (2017) (69)
Optimising experimental research in respiratory diseases: an ERS statement (2018) (67)
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence (2018) (67)
Sarilumab use in severe SARS-CoV-2 pneumonia (2020) (67)
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? (2017) (66)
Post-COVID lung fibrosis: The tsunami that will follow the earthquake (2020) (60)
The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. (2005) (59)
Repeated tuberculin testing does not induce false positive ELISPOT results (2006) (56)
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. (2016) (55)
“ERS/ATS Task Force onUndifferentiated Forms of CTD-ILD”. An official European RespiratorySociety/American Thoracic Society research statement: interstitial pneumonia withautoimmunefeatures (2015) (55)
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. (2013) (54)
Current approaches to the management of idiopathic pulmonary fibrosis. (2017) (53)
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension (2017) (52)
First report of the Italian register for diffuse infiltrative lung disorders (RIPID). (2001) (52)
T-Cell–Based Diagnosis of Neonatal Multidrug-Resistant Latent Tuberculosis Infection (2007) (52)
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. (2019) (51)
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials (2015) (50)
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis (2020) (49)
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772) (2018) (48)
Management of multidrug-resistant tuberculosis in Italy. (2005) (46)
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. (2021) (46)
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges (2012) (45)
Sarcoidosis: challenging diagnostic aspects of an old disease. (2012) (44)
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis (2017) (44)
Idiopathic Pulmonary Fibrosis: Prospective, Case‐Controlled Study of Natural History and Circulating Biomarkers (1987) (41)
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. (2004) (40)
The characterisation of interstitial lung disease multidisciplinary team meetings: a global study (2019) (40)
Diagnostic Likelihood Thresholds that Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. (2019) (38)
The big clinical trials in idiopathic pulmonary fibrosis (2012) (38)
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. (2014) (38)
X-ray Micro-Computed Tomography for Nondestructive Three-Dimensional (3D) X-ray Histology (2019) (37)
“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease (2018) (37)
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey (2020) (37)
Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. (2019) (35)
COVID-19 and intestinal inflammation: Role of fecal calprotectin (2020) (35)
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program (2011) (35)
Mycobacterium tuberculosis Induces CCL18 Expression in Human Macrophages (2008) (34)
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis (2018) (34)
Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China (2015) (33)
Nintedanib in the treatment of idiopathic pulmonary fibrosis (2015) (33)
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) (2020) (33)
Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis (2018) (33)
Rising to the Challenge of COVID-19: Advice for Pulmonary and Critical Care and an Agenda for Research (2020) (32)
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial (2021) (32)
Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy (2013) (30)
Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia (2015) (29)
Treatment strategies for asthma: reshaping the concept of asthma management (2020) (29)
Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis (2015) (29)
Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease (2014) (29)
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax. (2003) (29)
A systematically derived exposure assessment instrument for Chronic Hypersensitivity Pneumonitis. (2020) (29)
The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory (2019) (28)
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. (2002) (27)
Macrolides in the treatment of asthma and cystic fibrosis. (2005) (27)
Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice (2007) (27)
Lung ultrasonography for early management of patients with respiratory symptoms during COVID-19 pandemic (2020) (27)
Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. (2021) (27)
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts (2008) (27)
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: Results of two 52-week, Phase III, randomized, placebo-controlled trials (INPULSIS™) (2015) (26)
A global registry for idiopathic pulmonary fibrosis: the time is now (2014) (26)
Novel drug targets for idiopathic pulmonary fibrosis (2016) (26)
Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials (2019) (25)
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis (2013) (25)
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist (2017) (25)
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) (2020) (24)
Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials (2014) (24)
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases (2021) (24)
The complex interrelationships between chronic lung and liver disease: a review (2010) (24)
Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis (2019) (24)
Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies (2018) (24)
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis (2012) (24)
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage (2019) (23)
Utility of a Molecular Classifier as a Complement to HRCT to Identify Usual Interstitial Pneumonia. (2020) (23)
Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis (2018) (22)
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments (2015) (22)
Interferon gamma assays for tuberculosis. (2005) (22)
Molecular diagnosis of tuberculosis. (1995) (21)
Antibody repertoire against the A60 antigen complex during the course of pulmonary tuberculosis. (1993) (21)
The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress (2020) (21)
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry (2022) (21)
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy (2015) (20)
Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies (2017) (20)
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice (2018) (19)
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells (2006) (19)
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis (2020) (19)
Current Diagnosis and Management of Hypersensitivity Pneumonitis (2020) (19)
Idiopathic Pulmonary Fibrosis (2002) (18)
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. (2019) (18)
Pooled analysis of mortality data from the TOMORROW and INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (IPF) (2014) (18)
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients (2017) (18)
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. (2008) (18)
Recommendations on treatment for IPF (2013) (18)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary An Update of the 2011 Clinical Practice Guideline (2015) (18)
The role of biomarkers in low respiratory tract infections. (2012) (18)
The safety of new drug treatments for idiopathic pulmonary fibrosis (2016) (18)
Interferon-γ-Release Assays Detect Recent Tuberculosis Re-Infection in Elderly Contacts (2009) (18)
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. (2022) (18)
Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment (2022) (17)
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone (2018) (17)
S108 Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials (2015) (17)
Telemedicine-enabled Accelerated Discharge of Patients Hospitalized with COVID-19 to Isolation in Repurposed Hotel Rooms (2020) (17)
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient (2007) (17)
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF (2015) (16)
Rapid identification of Mycobacterium tuberculosis infection (2006) (16)
Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis: A TBNET Study (2009) (15)
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay (2008) (15)
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection (2009) (15)
Role of the Quantiferon-TB Test in Ruling Out Pleural Tuberculosis: A Multi-Centre Study (2011) (15)
Investigational drugs for idiopathic pulmonary fibrosis (2017) (15)
Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement (2018) (15)
Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management (2020) (14)
Residual respiratory impairment after COVID-19 pneumonia (2021) (14)
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data (2020) (14)
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae? (2021) (14)
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis (2020) (14)
Residual respiratory impairment after COVID-19 pneumonia (2021) (14)
Bidirectional epithelial–mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis (2021) (14)
Multidisciplinary Evaluation of Interstitial Lung Diseases: New Opportunities Linked to Rheumatologist Involvement (2020) (14)
An Of fi cial ATS / ERS / JRS / ALAT Clinical Practice Guideline : Treatment of Idiopathic Pulmonary Fibrosis : Executive Summary An Update of the 2011 Clinical Practice Guideline (2015) (14)
Emerging drugs for idiopathic pulmonary fibrosis (2011) (14)
Current and Future Idiopathic Pulmonary Fibrosis Therapy (2019) (13)
Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis (2021) (13)
Churg–Strauss syndrome in a case of asthma (2002) (13)
A Quantitative Proteomic Approach to Identify Significantly Altered Protein Networks in the Serum of Patients with Lymphangioleiomyomatosis (LAM) (2014) (13)
Bronchopulmonary actinomycosis associated with hiatal hernia. (2009) (13)
Update in Pulmonary Fibrosis 2018. (2019) (13)
[Screening of latent tuberculosis infection in health care workers by QuantiFERON-TB and tuberculin skin test]. (2007) (13)
Individualizing duration of antibiotic therapy in community-acquired pneumonia. (2017) (12)
S106 Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in IPF (2015) (12)
Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation. (2015) (12)
COVID-19 and Interstitial Lung Disease: Keep Them Separate (2020) (12)
Suggestions for lung function testing in the context of COVID-19 (2020) (12)
New treatment directions for IPF: current status of ongoing and upcoming clinical trials (2017) (12)
Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary results (2018) (12)
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments (2021) (11)
Long-term management of IPF with pirfenidone - a clinical case study with 5 years follow-up. (2013) (11)
Air pollution and acute exacerbations of idiopathic pulmonary fibrosis: back to miasma? (2014) (11)
Severe asthma: One disease and multiple definitions (2021) (11)
Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited (2019) (11)
Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics (2013) (11)
Validation of multidisciplinary diagnosis in IPF. (2018) (11)
Genetic testing in diffuse parenchymal lung disease (2012) (10)
Idiopathic pulmonary fibrosis: current challenges and future perspectives (2013) (10)
Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough (2015) (10)
What if we made stratified medicine work for patients? (2016) (10)
Twenty-four week decline in forced vital capacity (FVC) predicts mortality at week 52 in the INPULSIS trials (2016) (10)
Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions (2018) (10)
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. (2019) (10)
Serological markers predicting tuberculosis in human immunodeficiency virus-infected patients. (1997) (9)
Activities of human alveolar macrophages (HAMs). Note 1: Observations on phagocytosis and bacterial killing in the presence of miocamycin. (1988) (9)
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. (2022) (9)
Multidrug-resistant tuberculosis outbreak in an Italian prison: tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays (2016) (9)
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. (2011) (9)
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations (2018) (9)
The role of bronchoalveolar lavage cellular analysis in the diagnosis of interstitial lung diseases (2009) (9)
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis (2022) (9)
Macrolides for chronic asthma (Review) (2008) (9)
Analysis of sputum in COPD (2001) (9)
Bronchopulmonary Actinomycosis Associated With Hiatal Hernia (2009) (9)
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. (2011) (9)
Clinical trials of investigational agents for IPF: a review of a Cochrane report (2013) (9)
Viruses and acute exacerbations of idiopathic pulmonary fibrosis: rest in peace? (2011) (8)
Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials (2014) (8)
Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study (2019) (8)
A Culture-Proven Case of Community-Acquired Legionella Pneumonia Apparently Classified as Nosocomial: Diagnostic and Public Health Implications (2013) (8)
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life☆ (2021) (8)
The 2018 Diagnosis of IPF Guidelines: Surgical Lung Biopsy in Probable UIP is Not Mandatory. (2019) (8)
Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro‐con perspective (2015) (8)
Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? (2020) (8)
Role of the HLA-DP gene in susceptibility to lung granulomas. (1993) (8)
Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis (2014) (7)
A genetic marker for chronic beryllium disease. (1995) (7)
The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis (2019) (7)
Identification of two new DPB1 alleles, DPB1*7701 and *7801, by sequence-based typing. (1998) (7)
Treatment Of IPF With The Tyrosine Kinase Inhibitor BIBF 1120: Patient-Reported Outcomes In The TOMORROW Trial (2012) (7)
Possible Role of Chest Ultrasonography for the Evaluation of Peripheral Fibrotic Pulmonary Changes in Patients Affected by Idiopathic Pulmonary Fibrosis—Pilot Case Series (2020) (7)
S110 Efficacy and safety of nintedanib in patients with IPF beyond week 52: Data from the Phase II TOMORROW trial (2015) (7)
Antibody-based therapies for idiopathic pulmonary fibrosis (2020) (7)
Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. (2009) (7)
Chronic beryllium disease: a model for pulmonary sarcoidosis? (2005) (7)
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 (2021) (7)
Twenty‐five years of Respirology: Advances in idiopathic pulmonary fibrosis (2020) (6)
Pulmonary eosinophilic infiltrates. (2010) (6)
CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial (2022) (6)
No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib (2016) (6)
Co-trimoxazole effect on human alveolar macrophages of AIDS patients. (2011) (6)
Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit (2019) (6)
Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done? (2017) (6)
Reduction in disease progression with nintedanib in the INPULSIS™ trials (2014) (5)
Diagnosing latent tuberculosis infection: guess who's coming to dinner? (2009) (5)
Design of IPF Clinical Trials in the Era of Approved Therapies. (2019) (5)
Effects of nintedanib on dyspnoe, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial* (2020) (5)
To BAL or not to BAL: is this a problem in diagnosing IPF? (2009) (5)
Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study (2020) (5)
Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study (2020) (5)
Neuropsychiatric reactions induced by cycloserine in the treatment of multidrug-resistant tuberculosis: what an Indian female patient tells us (2019) (5)
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis (2021) (5)
Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality? (2019) (5)
Identifying patients with idiopathic pulmonary fibrosis: quality or quantity? (2007) (5)
Accuracy Of A Clinical Diagnosis Of Idiopathic Pulmonary Fibrosis: A Study Of 275 Pulmonologists From 54 Countries (2017) (5)
Reticulation is a Risk Factor of Progressive Subpleural non-Fibrotic Interstitial Lung Abnormalities. (2022) (5)
Management of idiopathic pulmonary fibrosis. (2012) (5)
Idiopathic pulmonary fibrosis: moving forward (2015) (5)
Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. (2018) (5)
COVID-related fibrosis: insights into potential drug targets (2021) (5)
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies (2021) (5)
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? (2010) (5)
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (2014) (4)
Interstitial Lung Disease in India. Keep Searching and You'll Keep Finding. (2017) (4)
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants. (2023) (4)
Accuracy and Predictors of Success of EUS-B-FNA in the Diagnosis of Pulmonary Malignant Lesions: A Prospective Multicenter Italian Study (2022) (4)
Steroid and/or other immunosuppressive therapies in idiopathic interstitial pneumonias: have they still a role? (2005) (4)
Obstructive sleep apnea in sarcoidosis and impact of cpap treatment on fatigue (2020) (4)
P9 Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis – initial clinical experience in a UK cohort (2015) (4)
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis (2010) (4)
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis (2011) (4)
Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey (2019) (4)
Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient (2016) (4)
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function (2022) (4)
Evaluation of the lung microbiome as a therapeutic target in the management of idiopathic pulmonary fibrosis: role of antioxidant/antibiotic combination therapy. (2019) (4)
Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends (2020) (4)
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis (2020) (4)
Contemporary Concise Review 2018: Interstitial lung disease (2019) (4)
How we will diagnose IPF in the future. (2016) (4)
Interstitial lung diseases (2009) (4)
A real-time integrated framework to support clinical decision making for covid-19 patients (2022) (4)
Recent Advances and Future Needs in Interstitial Lung Diseases (2016) (4)
Efficacy endpoints for idiopathic pulmonary fibrosis trials. (2015) (3)
Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis (2020) (3)
Rifabutin for treating pulmonary tuberculosis (Review) (2010) (3)
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials (2021) (3)
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial (2020) (3)
Progressive Fibrosing Interstitial Lung Disease: A Proposed Integrated Algorithm for Management. (2020) (3)
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? (2020) (3)
Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity (2019) (3)
COVID-19 atypical Parsonage-Turner syndrome: a case report (2022) (3)
Management of CAP using a validated risk score (2005) (3)
S12 Effect Of Baseline Fvc On Decline In Lung Function With Nintedanib: Results From The Inpulsis™ Trials (2014) (3)
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan (2013) (3)
Orphan Lung Diseases (2016) (3)
A Phase IIb Randomized Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. (2022) (3)
[New tools for a better diagnosis of latent tuberculosis infection]. (2006) (3)
M33 Long-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (ipf) irrespective of dose: subgroup analysis of inpulsis-on (2017) (3)
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis (2016) (3)
The Use of Chitotriosidase as a Marker of Active Sarcoidosis and in the Diagnosis of Fever of Unknown Origin (FUO) (2021) (3)
Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial* (2019) (3)
Efficacy of nintedanib on acute exacerbations reported as serious adverse events in the INPULSIS trials in idiopathic pulmonary fibrosis (IPF) (2017) (3)
Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis (2016) (3)
HIF pathway activation is a core regulator of collagen structure-function in lung fibrosis (2020) (2)
Identifying and managing sleep disorders in primary care (2015) (2)
Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): pooled data from six clinical trials (2019) (2)
Characteristics of Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) in the INBUILD Trial of Nintedanib (2019) (2)
Treatments for idiopathic pulmonary fibrosis. (2014) (2)
Additive effect of BI 1015550 and nintedanib in patients with IPF (2022) (2)
Sensitivity analyses from the INPULSIS™ trials of nintedanib (2014) (2)
Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply. (2018) (2)
Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study (2019) (2)
Phase 2b Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: SCENIC Trial: Multi-Center, Randomized, Placebo-Controlled Study. (2022) (2)
P070 Long-term efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the TOMORROW trial and its open-label extension (2016) (2)
M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf (2017) (2)
Targeted treatment of idiopathic pulmonary fibrosis: one step at a time (2016) (2)
A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: A SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement (2021) (2)
Interstitial lung disease in elderly subjects (2009) (2)
Role of Stenotrophomonas maltophilia isolation in patients with non CF bronchiectasis. (2020) (2)
Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) (2016) (2)
Smoking-related interstitial lung disease (2011) (2)
Amyotrophic lateral sclerosis and sarcoidosis: A difficult differential diagnosis (2010) (2)
The Oral Triple Kinase Inhibitor BIBF 1120 Reduces Decline In Lung Function In Patients With Idiopathic Pulmonary Fibrosis (IPF): Results From The Tomorrow Study (2011) (2)
Macrolides for chronic asthma. (2002) (2)
New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA (2019) (2)
Blood tests for diagnosis of tuberculosis – Authors' reply (2006) (2)
Efficacy Of The Tyrosine Kinase Inhibitor BIBF 1120 In Patients With IPF: Consistent Pattern Of Primary Endpoint Results In Sensitivity Analyses Of The TOMORROW Trial (2012) (2)
P089 Effect of baseline GAP index stage on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF) (2016) (2)
New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases (2020) (2)
The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol (2021) (2)
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis (2018) (2)
Interferon gamma-1b for pulmonary fibrosis. (2004) (2)
Restless legs syndrome: A new comorbidity in idiopathic pulmonary fibrosis. (2020) (2)
From pulmonary susceptible tuberculosis to extensively drug resistant tuberculosis: An interesting case report of a young Indian girl. (2020) (1)
Effect of baseline FVC on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS® trials (2016) (1)
Three-Dimensional Characterisation of Fibroblast Foci in Idiopathic Pulmonary Fibrosis (2016) (1)
Prognostic role of ultrasonographic air bronchogram in management of pneumoniae in children (2019) (1)
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? (2014) (1)
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis. (2022) (1)
Chapter 4 – Management of Idiopathic Pulmonary Fibrosis (2018) (1)
Effect of baseline statin use on benefit of nintedanib (2016) (1)
COPD management as a model for all chronic respiratory conditions: report of the 4th Consensus Conference in Respiratory Medicine (2017) (1)
Diagnosis and treatment of idiopathic pulmonary fibrosis 2 (2015) (1)
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years (2022) (1)
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease (2016) (1)
The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities (2019) (1)
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study (2012) (1)
A decade of interferon-γ release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis? (2011) (1)
Managing patients with interstitial lung disease: Two more pieces of the puzzle (2017) (1)
Diagnosis of Idiopathic Pulmonary Fibrosis An Of fi cial ATS / ERS / JRS / ALAT Clinical Practice Guideline : Executive Summary (2018) (1)
S99 Efficacy of nintedanib on acute exacerbations reported as serious adverse events in the inpulsis® trials in idiopathic pulmonary fibrosis (IPF) (2016) (1)
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study (2022) (1)
Corticosteroids for idiopathic pulmonary fibrosis (Review) (2010) (1)
Long-Term Safety and Efficacy of Recombinant Human Pentraxin-2 in Patients with Idiopathic Pulmonary Fibrosis (2019) (1)
Agreement Between Pulmonologists For The Diagnosis Of Interstitial Lung Disease: A Study Of 275 Pulmonologists From 54 Countries (2017) (1)
Phase three clinical trials in idiopathic pulmonary fibrosis (2021) (1)
Possible role of chest ultrasonography for the evaluation of peripheral fibrotic changes in patients affected by IPF (2019) (1)
P8 Pooled analysis of data from the TOMORROW and INPULSIS® trials of nintedanib in IPF (2015) (1)
Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY (2017) (1)
Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? (2020) (1)
M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf (2017) (1)
First insights from the BTS idiopathic pulmonary fibrosis (IPF) registry (2016) (1)
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis (2013) (1)
Pooled analysis of data from the TOMORROW and INPULSIS® trials of nintedanib in IPF (2016) (1)
Macrolides for chronic asthma. (2005) (1)
ROLE OF QUANTIFERON-TB GOLD TEST IN THE DIAGNOSIS OF ACTIVE TUBERCULOSIS (2010) (1)
Interstitial lung diseases. Preface. (2012) (1)
Acute Respiratory Distress Syndrome and Lung Fibrosis Complicating Surgery in a Patient With Crohn's Disease. (2021) (1)
Novel drug targets in idiopathic pulmonary fibrosis (2019) (1)
Treatable traits in interstitial lung diseases: a call to action. (2023) (1)
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply. (2022) (0)
What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review (2019) (0)
Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis. (2017) (0)
Differential effects of the histone deacetylase (HDAC) inhibitor, Romidepsin (FK228), on IPF fibroblasts and alveolar epithelial cells. (2014) (0)
High Throughput Proteomic Analysis of serum from patients with Lymphangioleiomyomatosis (2014) (0)
Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155) (2014) (0)
Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis) (2022) (0)
Radiological findings of inactive tuberculosis do not correlate with M. tuberculosis-specific T-cell immunity in high risk patients (2008) (0)
La Cochrane-review (2011) (0)
Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations (2018) (0)
Late Breaking Abstract - The TRITRIAL COPD study: preliminary baseline patient characteristics collected during the COVID-19 pandemic (2021) (0)
Therapeutic approaches to idiopathic pulmonary fibrosis (2004) (0)
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis (2013) (0)
Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis (2022) (0)
Novel PDE4B inhibitor offers breakthrough for IPF (2022) (0)
Determinants and evolution of obstructive sleep apnea syndrome after myocardial infarction (2019) (0)
PERFORMANCE OF QUANTIFERON-TB GOLD IN-TUBE IN PATIENTS WITH NON-TUBERCULOUS MYCOBACTERIAL DISEASE (2010) (0)
Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Non-IPF Fibrotic Interstitial Lung Disease. (2021) (0)
Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis. (2018) (0)
PP399 Analysis Of Referral Patterns To Specialized Centers In Idiopathic Pulmonary Fibrosis To Define A New Regional Care Pathway (2020) (0)
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial (2012) (0)
Statin Therapy and Lung Disorders (2019) (0)
[Role of in vitro tests in the diagnosis of latent tubercular infections]. (2010) (0)
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease (2013) (0)
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung (2014) (0)
Use of digital auscultation in patients with ARDS: a correlation study with CT imaging (2020) (0)
P079 Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) (2016) (0)
Identifying Opportunities for Earlier IPF Diagnosis (2018) (0)
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience (2012) (0)
Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis (2018) (0)
Safety and Efficacy of BI 1015550, a Preferential Inhibitor of Phosphodiesterase 4b, in Patients with Idiopathic Pulmonary Fibrosis: A Phase 2 Trial (2022) (0)
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges (2012) (0)
Key ongoing issues in trial design (2016) (0)
Alveolar and Fibroblast Foci Specific Genome-Wide Gene Expression Profiling Identifies Common Dysregulated Expression of CREB1, a Regulator Across Cell Types, in IPF (2019) (0)
Blood Tests for Latent Tuberculosis in Patients with Chronic Liver Disorders: A Prospective Study. (2009) (0)
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) beyond week 52: Data from the Phase II TOMORROW trial (2016) (0)
Treatment With BIBF 1120 Reduces Acute Exacerbations And Improves Quality Of Life In Patients With IPF: Results From The Tomorrow Study (2011) (0)
Analysis of the antigen-specific t-cell response in patients with chronic obstructive pulmonary disease (2009) (0)
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients (2005) (0)
SAFETY OF NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): LONG-TERM GLOBAL PHARMACOVIGILANCE DATA (2019) (0)
Ventilatory Support in Patients with COVID-19. (2021) (0)
Blood Tests for Tuberculosis Infection in Patients with Haematological Malignancies: A Prospective Study. (2009) (0)
Ultrasonographic assessment of diaphragm dysfunction in acute exacerbations of COPD (2017) (0)
Ultrasound-guided needle aspiration biopsy of anterior mediastinal masses in the hands of pulmonologists (2022) (0)
Global characterisation of routine care interstitial lung disease diagnostic practice (2017) (0)
Reply to Moran-Mendoza: Idiopathic Pulmonary Fibrosis Update. Reconciliation with Hypersensitivity Pneumonitis Guidelines Required? (2022) (0)
Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease (2008) (0)
[Mycobacterium tuberculosis. From the gene to the diagnosis]. (1992) (0)
SESSION 4 IGRAs in populations with comorbidities. (2010) (0)
Novel insights in fibrotic pulmonary sarcoidosis (2022) (0)
Data for: Restless legs syndrome: a new comorbidity in idiopathic pulmonary fibrosis (2021) (0)
Accuracy and safety of EUS-B-FNA in the diagnosis of lung parenchymal lesions (2018) (0)
Summary for Clinicians: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults. (2023) (0)
Hypoxia-inducible factor pathway activation promotes bone-type collagen cross-linking in Idiopathic Pulmonary Fibrosis (2019) (0)
Interstitial Lung Disease, An Issue of Clinics in Chest Medicine (2012) (0)
Circulating Autoantibodies Are Associated With Longer Survival Time In Idiopathic Pulmonary Fibrosis (2012) (0)
Envisia Genomic Classifier Demonstrates Consistent Performance Across Gender, Age Group, and Smoking Status (0)
Effect of baseline FVC on preservation of lung function with BIBF 1120: Results from the TOMORROW trial (2011) (0)
Epidemiology and Effect of Therapy in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF) (2019) (0)
Challenges in idiopathic interstitial lung disease (2015) (0)
Diagnosis and treatment of idiopathic pulmonary fibrosis 1 (2015) (0)
Home oxygen saturation monitoring and quality of life in patients with idiopathic pulmonary fibrosis: A prospective multicenter trial (2013) (0)
Prior tuberculin skin test does not induce a false positive result of T-cell interferon-gamma release assays (2008) (0)
Smoking-related interstitial lung (2011) (0)
The reply. (2013) (0)
Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of GAP Stage at Baseline in the INPULSIS Trials (2016) (0)
P103 Automated quantitative imaging correlates with lung function and exercise tolerance in patients with idiopathic pulmonary fibrosis. (2016) (0)
Correction to: Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China (2021) (0)
Dataset for X-ray micro-computed tomography for non-destructive 3D X-ray histology (2019) (0)
Use of Quantiferon-TB in tube test in the diagnosis of non tuberculous mycobacteria lung disease. (2010) (0)
Does excluding subjects with features similar to IPF affect the results of the INBUILD trial of nintedanib? (2020) (0)
Re-dimensioning the treatment paradigm in idiopathic pulmonary fibrosis (2018) (0)
Endogenous blood maximal interferon-γ production may predict response to interferon-γ 1 β treatment in patients with idiopathic pulmonary fibrosis (2009) (0)
Effect of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis and Differing Extents of Emphysema on HRCT (2023) (0)
Functional activities of human alveolar macrophages. (1990) (0)
Next-Generation Interstitial Lung Disease (2021) (0)
Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new (2020) (0)
P279 Reduction In Disease Progression With Nintedanib In The Inpulsis™ Trials (2014) (0)
Chapter 43 – Diagnosis (2002) (0)
Diagnosis of latent tuberculosis in children immigrants from countries with high tuberculosis prevalence (2010) (0)
HRCT in the diagnosis of interstitial lung disease (2013) (0)
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation (2005) (0)
Lymphokines and the lung. (1997) (0)
Circulating peripheral blood stem cells in idiopathic pulmonary fibrosis: a role for fibrocytes and endothelial cells (2008) (0)
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don’t (2020) (0)
Impact of QuantiFERON GOLD In-Tube test in contact tracing among immigrants from high prevalence countries (2008) (0)
Therapeutic approach and molecular targets for novel treatments (2015) (0)
Sarcoidosis in the UK: Insights from the BTS interstitial lung disease registry (2016) (0)
Associations Between Semi-quantitative HRCT Features and Outcomes in Patients With IPF: Data From the INPULSIS Trials (2023) (0)
Methylprednisolone pulse therapy in Acute Exacerbations of Idiopathic Pulmonary Fibrosis (2020) (0)
Performance and Clinical Utility of the Genomic Classifier (Envisia) for Usual Interstitial Pneumonia in Conjunction with Local Radiology (2020) (0)
Proceedings of the Second Global Symposium on Interferon-Gamma Release Assays: Introduction. (2010) (0)
Minimal Clinical Important Difference (MCID) for Visual Assessment of Pulmonary Fibrosis on Chest High Resolution Computed Tomography Scan (HRCT) (2022) (0)
Epidemiology and Diagnosis of Idiopathic Pulmonary Fibrosis (2020) (0)
Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going (2012) (0)
Late Breaking Abstract - Prevalence and clinical significance of antinuclear antibody (ANA) in IPF: analysis from ESTAIR study (2018) (0)
Mediastinal Lymph Node Enlargement Predicts Significant Functional Decline in Idiopathic Pulmonary Fibrosis (2020) (0)
Characterisation of a novel in vitro model of fibroblastic foci (2014) (0)
Blood tests for diagnosis of tuberculosis - Reply (2006) (0)
Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone? (2020) (0)
Cardiopulmonary Exercise Test Profile in Hypersensitivity Pneumonitis (2020) (0)
Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region (2022) (0)
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis (2014) (0)
Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study (2021) (0)
Looking Ahead: Interstitial Lung Disease Diagnosis and Management in 2030. (2021) (0)
T-cell Interferon-gamma-release assays performance to detect latent tuberculosis infection in immunocompromised patients (2008) (0)
Mindfulness-based stress reduction in patients with interstitial lung diseases : a pilot , single-centre observational study on safety and ef fi cacy (2015) (0)
Malattie infiltrative diffuse del polmone (2017) (0)
The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials? (2022) (0)
Rapid diagnosis of tuberculous pleuritis by enumeration of MTB-specific cells from pleural effusions (2007) (0)
Pharmacologic Treatment of IPF (2018) (0)
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report (2016) (0)
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology (2014) (0)
Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) for Idiopathic Pulmonary Fibrosis: Study Design of STARSCAPE, A Phase III Randomized Double Blind Placebo Controlled Trial (2021) (0)
Closing remarks. (2020) (0)
HLA and Respiratory Disease (2000) (0)
Reply to Huang and Wei, Kang et al., and Ehteshami-Afshar and Raj (2022) (0)
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants (2011) (0)
Hermansky-Pudlak Syndrome Subtype 4 (HPS-4): A Novel Mutation in a 44 Years Old Italian Woman with Severe Pulmonary Fibrosis (2019) (0)
Combining immunostaining with micro-computed tomography to visualise the 3D distribution of mast cells in idiopathic pulmonary fibrosis (2016) (0)
THU0404 Esophageal involvement predicts pulmonary function deterioration in patients with systemic sclerosis (2018) (0)
Ultrasound-guided needle aspiration biopsy of isolated anterior mediastinal masses. (2022) (0)
Diagnosis of latent tuberculosis infection in patients with hematological malignancies: use of the new IFN-gamma-based blood tests (2007) (0)
Pre-treatment endogenous interferon-gamma T cell response may predict efficacy of interferon-gamma 1 beta therapy in patients with idiopathic pulmonary fibrosis (2006) (0)
Cyclophosphamide for interstitial lung disease (2009) (0)
Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials? (2015) (0)
Progress and Innovation in Interstitial Lung Disease. (2021) (0)
Recommended Reading from the Fondazione Policlinico Universitario A. Gemelli IRCCS Fellows. (2019) (0)
AB0342 Rheumatoid Arthritis Related Interstitial Lung Disease. Radiological Patterns and Correlations with Clinical, Serological and Demographic Features of Disease (2014) (0)
Consistent effect of nintedanib in patients with IPF and degrees of impairment in gas exchange* (2019) (0)
The Guest Editors (2009) (0)
Impact of Chest CT Quality on the Diagnosis of Usual Interstitial Pneumonia (UIP) Pattern: A Hub and Spoke Study (2019) (0)
Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib. (2023) (0)
Unexpected identification of bilateral masses in an asymptomatic heavy smoker (2010) (0)
Author ' s personal copy Management of Idiopathic Pulmonary Fibrosis (2012) (0)
Challenges in the diagnosis of idiopathic pulmonary fibrosis: the importance of a multidisciplinary approach (2023) (0)
Late Breaking Abstract - Investigation of the epithelial-mesenchymal paracrine interactions in lung tissue repair and fibrosis (2019) (0)
Supplementary Material for: Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis (2018) (0)
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience (2012) (0)
IPF: treatment and prevention of pulmonary exacerbations (2017) (0)
Interstitial pneumonia with autoimmune features (IPAF): a clinical entity? (2019) (0)
False Negative IGRA In Active Tuberculosis: The FIAT 500 Study (2012) (0)
Eosinophilic globules in bronchoalveolar lavage fluid of patients with systemic sclerosis-related interstitial lung disease: a diagnostically useful, previously unreported finding in a retrospective and prospective study, including differential diagnosis with other idiopathic and secondary interstit (2008) (0)
X-ray micro-computed tomography for non- destructive 3D X-ray histology Authors (2019) (0)
Monitoring small airway dysfunction in connective tissue disease-related interstitial lung disease: a retrospective and prospective study (2023) (0)
Understanding the Decision-Making Process of the Multidisciplinary Approach for the Diagnosis of Interstitial Lung Disease: A Qualitative Study (0)
Reply to Fenton et al.: An Expanded COVID-19 Telemedicine Intermediate Care Model Using Repurposed Hotel Rooms (2020) (0)
The role of gamma-interferon tests for suspected tuberculous ocular inflammation (2008) (0)
Author response for "Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies" (2021) (0)
Safety and efficacy of pamrevlumab (FG-3019) in patients with COVID-19 pneumonia: an open-label, randomized, parallel-arm phase 2 study (2022) (0)
Prevalence and association with malignancy of intrathoracic lymph node calcifications: a cross sectional endosonographic pilot study (2022) (0)
Design of Phase III, Randomized, Placebo-Controlled Trials of BI 1015550 in Patients with Progressive Fibrosing Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis (FIBRONEER-ILD / -IPF) (2023) (0)
Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS® trials in idiopathic pulmonary fibrosis (IPF) (2016) (0)
BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF) (2023) (0)
Impact of QuantiFERON-TB and T-SPOT.TB tests in contact tracing among patients with chronic renal failure (2008) (0)
Correlation between lung sounds and HRCT signs of pulmonary fibrosis: a blinded prospective study (2017) (0)
Idiopathic pulmonary fibrosis: state of the art for 2023 (2023) (0)
Advances with pharmacotherapy for the treatment of interstitial lung disease (2021) (0)
Reply to: Cottin et al., Johannson et al., Scholand and Wells, and Crowley et al. (2023) (0)
Impact of comorbidities in interstitial pneumonia with autoimmune features (IPAF) (2019) (0)
Reply to Moodley and to Ravaglia et al. (2019) (0)
Investigation of the epithelial-mesenchymal trophic unit in idiopathic pulmonary fibrosis (2019) (0)
Efficacy of BIBF 1120 in patients with IPF is dose-dependent: Results from the TOMORROW trial (2011) (0)
Pulmonary Fibrosis and the Many Faces of UIP (2015) (0)
The Use of Human Immunoglobulin in the Treatment of COVID-19 Pneumonia in Hematologic Patients a Single-Center Case Series (2023) (0)
287-PA10 Evaluation of serological testing for the assessment of M. tuberculosis (M.tb) latent infection (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luca Richeldi?

Luca Richeldi is affiliated with the following schools: